How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies

Patients with hematologic malignancies and recipients of hematopoietic cell transplantation (HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have a higher risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: El Chaer, Firas, Auletta, Jeffery J., Chemaly, Roy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
How I Treat
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249429/
https://www.ncbi.nlm.nih.gov/pubmed/35776899
http://dx.doi.org/10.1182/blood.2022016089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249429/
https://www.ncbi.nlm.nih.gov/pubmed/35776899
http://dx.doi.org/10.1182/blood.2022016089

Ejemplares similares